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Background: Standard stratiﬁcation criteria in studies evaluating 
patients (pts) with locally advanced NSCLC generally include gender, 
stage, & weight loss, occasionally age and histology. However, con-
temporary analyses of more recent trials in LA-NSCLC to determine if 
these factors are still prognostic have not been conducted. 
Materials and Methods: We evaluated the baseline demographics of 
two separate phase III trials: (1) RTOG 9410, a randomized phase III 
trial in good prognosis LA-NSCLC comparing sequential cisplatin-
based chemotherapy followed by RT (63 Gy) to concurrent chemother-
apy & either once daily RT (63Gy) or twice daily (BID) RT (69.6 Gy) 
(platinum dose in each arm was equivalent) & (2) RTOG 9801, a phase 
III trial evaluating induction chemotherapy with paclitaxel & carbopla-
tin followed by concurrent BID RT, weekly paclitaxel & carboplatin ± 
amifostine. We assessed the distribution of prognostic variables in each 
study, & then analyzed hazard ratios, conﬁdence intervals, & p values 
for each potential prognostic factor, including age, stage, N status, 
histology, gender, KPS, tumor location, and hemoglobin. We then as-
sembled risk models with multiple prognostic factors in combination.
Results: 824 evaluable pts were accrued to these 2 efforts: 585 to 
RTOG 9410; 239 to RTOG 9801. 82% were under 70; 56% had stage 
IIIB NSCLC, 37% had squamous histology. 64% were male. 19% had 
N0-1 disease, 53% N2, 27% N3. KPS was 90-100 in 75%. 22% had 
primary tumor location in the lower lobe or multiple lobes. Baseline 
median hemoglobin was 13.4; 17% had baseline hemoglobin under 12. 
At this point 110 patients (13% of total enrollment) remain alive; 10% 
of those enrolled on 9410 with a median follow-up of 6 yrs, & 22% of 
those on 9801 with a median follow-up of 3 yrs. In univariate analysis 
by Cox modeling, KPS (90-100 versus 70-80; p=0.0002) & N status 
(N0 vs N1 vs N2 vs N3, p=0.0048) were highly prognostic; gender 
(female vs male; p=0.0481) & lobar location (upper lobe versus lower 
or multilobe; p=0.0206) were borderline prognostic. Age (<70 vs. >70, 
p=0.28), stage (II/IIIA vs. IIIB, p=0.16), histology (non-squamous vs. 
squamous, p=0.085) & hemoglobin (<12 vs. < 12, p=0.62) were not 
prognostic. 
Age, stage, gender, N status (0, 1 vs 2, 3), KPS, histology, tumor loca-
tion & Hgb were dichotomized into 2 levels, one level corresponding 
with a worse prognosis, the other a better prognosis; pts were then 
grouped into three cohorts of combined poor prognosis factors 0, 1 vs 
2, 3 vs >3. The distribution and hazard ratios follow:
# of Prognostic 
Factors
9410 
(n-578)
9801 
(n=232)
Total 
(n=810)
HR 95% CI p value
MS 
(mos)
0, 1 41 (7%) 22 (9%) 63 (8%) 1.00 - - - - 22.7
2, 3 308 (53%)
120 
(52%)
428 
(53%) 1.31 (0.99, 1.79) 0.0585 17.3
>3 229 (40%) 90 (39%)
319 
(39%) 1.74 (1.28, 2.35) 0.0003 13.5
 
Conclusions: Independently, KPS, tumor location, N status, & gender 
have proven prognostic in platinum-based RTOG trials. However, 
prognostic modeling in LA-NSCLC, in the setting of non-operative 
combined modality therapy, is best performed by assessing multiple 
risk factors simultaneously rather than 1 variable at a time. Our evi-
dence-based joint analysis improves our prognostic ability & consti-
tutes a more clear-headed approach toward therapeutic stratiﬁcation in 
the presence of multiple prognostic variables. Observations from this 
analysis will help determine future stratiﬁcations in RTOG trials. 
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Background: Our previous IPD meta-analyses of CT in locally ad-
vanced NSCLC suggested that adding sequential CT to radiotherapy 
improved survival (BMJ 1995;311:899) and that adding concomitant 
CT to radiotherapy could also improve survival (inconsistent results in 
sensitivity analyses) (Ann Oncol 2006;17:473). The NSCLC Collabora-
tive Group reports here the update of these meta-analyses.
Methods: Systematic searches for RCTs were followed by central 
collection, checking and re-analysis of updated IPD. Results from indi-
vidual trials were combined using the stratiﬁed (by trial) log-rank test 
to calculate pooled hazard ratios (HRs). Previously included old trials 
using deleterious long-term alkylating agents were excluded from the 
updated sequential CT analysis.
Results: 31 RCTs were eligible for the meta-analysis of sequential CT. 
IPD was received from 21 RCTs (3473 patients) and only survival HR 
from one RCT (366 patients, IPD soon available). The survival analysis 
was based on these 22 trials and 3839 patients (78% of all known 
randomised patients). This adds 5 trials (1471 patients) to the 1995 
analysis. Median follow-up was 6.9 years. Sixteen trials used induction 
CT±alternated or consolidation CT, 7 used consolidation±concomitant 
CT or alternated CT. One trial had one part on induction and another 
